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A b s t r a c t
Introduction: Patients with established coronary artery disease (CAD) are at 
high risk of recurrent cardiovascular events. The aim of the analysis was to 
compare time trends in the extent to which cardiovascular prevention guide-
lines have been implemented by primary care physicians and specialists.
Material and methods: Five hospitals with cardiology departments serving 
the city and surrounding districts in the southern part of Poland participat-
ed in the study. Consecutive patients hospitalized due to an acute coronary 
syndrome or for a  myocardial revascularization procedure were recruited 
and interviewed 6–18 months after hospitalization. The surveys were car-
ried out in 1997–1998, 1999–2000, 2006–2007 and 2011–2013. 
Results: The proportion of smokers increased from 16.0% in 1997–1998 to 
16.4% in 2011–2013 among those who declared that a cardiologist in a hos-
pital outpatient clinic decided about the treatment, from 17.5% to 34.0% 
(p < 0.01) among those treated by a primary care physician, and from 7.0% 
to 19.7% (p = 0.06) among patients treated in private cardiology practices. 
The corresponding proportions were 44.6% and 42.4% (p < 0.01), 47.7% and 
52.8% (p = 0.53), 44.2% and 42.2% (p = 0.75) for high blood pressure, and 
42.5% and 71.2% (p < 0.001), 51.4% and 79.6% (p < 0.001), 52.4% and 72.4% 
(p < 0.01) for LDL cholesterol level not at recommended goal. The propor-
tion of patients prescribed cardioprotective medications increased in every 
analyzed group. 
Conclusions: The control of cardiovascular risk in CAD patients has only 
slightly improved since 1997/98 in all health care settings. The greatest po-
tential for further improvement was found among patients whose post-hos-
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Introduction
Patients with established coronary artery dis-
ease (CAD) are at high risk of recurrent cardiovas-
cular events. Despite advances in pharmacologi-
cal and invasive treatment methods, risk factors 
remain independent predictors of cardiovascular 
mortality in CAD patients [1]. Smoking cessation, 
providing advice on diet and physical activity and 
ensuring optimal pharmacological treatment are 
crucial factors in reducing mortality in patients 
who have suffered from myocardial infarction 
[2]. Thus, in the case of preventive cardiology the 
highest priority has been given to patients with 
established CAD [3].
The Cracovian Program for Secondary Preven-
tion of Ischaemic Heart Disease was launched in 
1997. The main goal of the program was to as-
sess and improve the quality of clinical care in the 
secondary prevention of CAD in Krakow. The first 
results showed insufficient implementation of 
CAD prevention guidelines in clinical practice and 
considerable potential for a  further reduction of 
cardiovascular risk in CAD patients [4]. The same 
hospitals participated in surveys in 1999–2000, 
2006–2007 and 2011–2013 [5–8], which similar-
ly to the EUROASPIRE surveys [9–11] evaluated 
the implementation of cardiovascular prevention 
guidelines. 
Polish society has undergone profound chang-
es triggered by the change of the political system 
in 1989 and by entering the European Union in 
2004. Poland’s healthcare system has been in 
transition for the last 20 years, both in terms of 
institutional changes and regulations regarding 
drug registration, prescription, and reimburse-
ment. More specifically, the relative position of 
primary care physicians in regard to specialists 
has evolved. 
Therefore, our aim was to compare time trends 
in the extent to which cardiovascular prevention 
guidelines have been implemented by primary 
care physicians and specialists. 
Material and methods
The study participants and the methods used 
have been described in previous reports [4–8]. 
A brief description relevant to the presented anal-
ysis is given below.
Five hospitals serving the city and surrounding 
districts in southern Poland participated in the sur-
veys. The total population of this area is approxi-
mately 1 200 000. In each cardiac department the 
medical records were reviewed and consecutive 
patients hospitalized due to acute myocardial in-
farction, unstable angina, or percutaneous coronary 
intervention (PCI), or scheduled for coronary artery 
bypass grafting (CABG), were identified retrospec-
tively, excluding those who had died during their 
in-hospital stay. Participants were invited to attend 
a follow-up examination 6 to 18 months after their 
discharge. The patients who declared they had no 
regular health check-ups after the discharge from 
the hospital were excluded from the present anal-
ysis. The surveys were carried out in 1997–1998, 
1999–2000, 2006–2007 and 2011–2013. 
Data on demographic characteristics, patients’ 
personal history of CAD, smoking status, blood 
pressure, fasting glucose, plasma lipids, and pre-
scribed medications were obtained using a stan-
dardized data collection form. Patients’ height 
and weight were measured in a standing position 
without shoes and heavy outer garments using 
standard scales with a  vertical ruler. The body 
mass index (BMI) was calculated according to the 
following formula: BMI = weight [kg]/(height [m])2. 
Blood pressure was measured twice, on the right 
arm in a  sitting position after at least 5 min of 
rest. For plasma lipid and glucose measurements 
a fasting venous blood sample was taken between 
7.30 and 8.30 in the morning. 
The secondary prevention coefficient was cal-
culated as follows: for each risk factor controlled 
(non-smoker, blood pressure < 140/90 mm Hg, 
low-density lipoprotein (LDL) cholesterol at rec-
ommended goal (< 3.5 mmol/l in 1997–1998 [12], 
< 3.0 mmol/l in 1999–2000 [13], < 2.5 mmol/l in 
2006–2007 [14], and < 1.8 mmol/l in 2011–2013 [3, 
15]), fasting glucose < 7.0 mmol/l, BMI < 30 kg/m2 
during the follow-up interview) one point was 
given. Additionally, one point was awarded for 
taking an antiplatelet or an antithrombotic agent, 
one point for taking an angiotensin convertase 
enzyme (ACE) inhibitor or a sartan, and one point 
for taking a β-blocker in patients with heart fail-
ure or myocardial infarction in the history. Thus, 
the secondary prevention coefficient could vary 
from 1 to 8. 
For the purposes of the present analysis the 
study participants were grouped according to 
their answers to the question: “Who decides 
about your treatment?”
pital care is provided by primary care physicians. It is associated with promotion of a no-smoking policy and 
enhanced prescription of guideline-recommended drugs.
Key words: coronary artery disease, secondary prevention, cardiovascular risk, smoking, cholesterol, blood 
pressure.
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Statistical analysis
Categorical variables were reported as per-
centages and continuous variables as means 
± standard deviation. The Pearson χ2 test was 
applied to all categorical variables. Normally dis-
tributed continuous variables were compared 
using Student’s t test or analysis of variance. 
Variables without normal distributions were 
evaluated using the Mann-Whitney U test or the 
Kruskal-Wallis analysis of variance. Multivariate 
analyses were performed using the generalized 
linear model as implemented in the Statistica 8.0 
software (StatSoft INC., Tulsa, USA). A two-tailed 
p-value of less than 0.05 was regarded as statis-
tically significant. 
Results
Overall, the data of 1924 patients (408 studied 
in 1997–1998, 419 in 1999–2000, 497 in 2006–
2007, and 600 in 2011–2013) were included to 
the present analysis. Mean age of the participants 
of the first, second, third and fourth surveys was 
57.9 ±8.3, 58.7 ±8.1, 62.3 ±8.9, and 64.8 ±8.8 years 
(p < 0.05), respectively. The proportions of women 
were 27.0%, 30.8%, 30.0%, and 35.3% (p < 0.05), 
respectively. There was no significant difference in 
the mean duration of education (11.3 ±3.6, 11.6 
±3.5, 11.6 ±3.4 and 11.9 ±3.2, respectively). Out of 
408 participants of the first survey, 188 (46.1%) 
declared that their treatment had been decided 
by a cardiologist or physician in a hospital outpa-
tient clinic, another 177 (43.4%) reported that the 
decisions had been made by a primary care phy-
sician and 43 (10.5%) by a physician in a private 
cardiology practice. The corresponding numbers in 
the second survey were 149 (35.6%), 232 (55.4%) 
and 38 (9.1%), in the third survey 268 (53.9%), 172 
(34.6%) and 57 (11.5%), whereas in the last sur-
vey the figures were 481 (80.2%), 53 (8.8%) and 
66 (11.0%). The characteristics of the participants 
according to practice setting are presented in Table 
I. Patients who declared that a general practitioner 
had decided on their treatment were significantly 
younger, less educated, were more often profes-
sionally active, more often had undergone CABG 
and less often PCI as index events compared to 
the other study groups. Based on their hospital re-
cords, patients who declared that their treatment 
had been planned by a general practitioner were 
more often smokers and suffered less often from 
dyslipidemia or obesity (Table I). These patients 
were less frequently prescribed antiplatelets, 
β-blockers, ACE inhibitors or sartans, and lipid-low-
ering agents on their discharge from the hospital. 
The proportions of patients with non-controlled 
risk factors 6–18 months after discharge are pre-
sented in Table II. The participants of the third and 
fourth surveys were significantly more likely to be 
smokers compared to the first and second sur-
veys. The time trends were similar in all three ana-
lyzed groups (the interaction between groups and 
surveys was not significant (p = 0.68)). In general, 
those patients who reported that a general prac-
titioner had decided about their treatment were 
more frequently smokers in the post-discharge 
period compared to other groups. We repeated 
all the analyses after smoking in the pre-hospital-
ization period had been included in the statistical 
model, and we found very similar results (data not 
shown). 
We did not find any evidence of different time 
trends (p-value for the interaction: 0.24) in blood 
pressure control between the analyzed groups (Ta-
ble II). We repeated all the analyses after including 
hypertension as diagnosed during the index hos-
pitalization in the statistical model, and we found 
very similar results (data not presented).
The proportions of patients with LDL cholester-
ol level not at goal differed between surveys both 
when we analyzed all participants as well as when 
we limited the analysis to specific groups (Table II). 
The time trends did not differ significantly be-
tween the analyzed groups (p = 0.62). We repeat-
ed all the analyses after including dyslipidemia 
as diagnosed during the index hospitalization in 
the statistical model, and we found very similar 
results (data not shown). When we applied the 
currently recommended treatment goal (LDL cho-
lesterol < 1.8 mmol/l), we found a significant im-
provement in the control of LDL cholesterol level: 
4.1% in the first survey, 1.2% in the second survey, 
22.1% in the third, and 27.9% in the fourth survey 
(p < 0.001). We found similar time trends when 
we analyzed specific groups: 6.1% vs. 1.4% vs. 
22.9% vs. 28.8% (p < 0.001) in the case of those 
who declared that a  cardiologist or a  physician 
in a hospital outpatient clinic had decided about 
their treatment, 2.3% vs. 1.3% vs. 18.3% vs. 20.4% 
(p < 0.001) in participants who declared that a prima-
ry care physician had decided about the treatment, 
and 2.5 vs. 0.0% vs. 29.8% vs. 27.6% (p < 0.001) in 
patients treated in private cardiology practices. 
We found increasing proportions of study par-
ticipants who were obese (p-value for interaction 
between surveys and groups: 0.20). Although 
the proportion of patients with fasting glucose 
≥ 7.0 mmol/l increased significantly, only in those 
who declared that a  cardiologist or physician in 
a  hospital outpatient clinic had decided about 
their treatment was the interaction between sur-
veys and groups not significant (p = 0.77). We re-
peated all the analyses after the presence of dia-
betes and obesity during the index hospitalization 
had been included in the statistical model, and we 
found very similar results (data not shown).
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The proportions of patients taking cardiopro-
tective medications are presented in Table III. We 
found significant differences between the surveys 
for every studied drug class. We also observed 
a significant increase in the use of statins in the 
group as a whole (19.9% vs. 34.6% vs. 84.9% vs. 
84.7%, p < 0.001) as well as when we analyzed 
specific groups: 36.2% vs. 48.3% vs. 84.6% vs. 
86.9% (p < 0.001) in the case of those who de-
clared that a cardiologist or physician in a hospi-
tal outpatient clinic decided about the treatment, 
5.1% vs. 27.6% vs. 86.6% vs. 69.8% (p < 0.001) in 
the case of participants who declared that a pri-
mary care physician had decided about their treat-
ment, and 9.3% vs. 23.7% vs. 80.7% vs. 80.3% 
(p < 0.001) in the case of patients treated in pri-
vate cardiology practices. The use of fibrates de-
creased in the group as a whole (14.0% vs. 7.9% 
vs. 3.9% vs. 2.3%, p < 0.001) as well as when 
we analyzed specific groups: 12.2% vs. 8.7% vs. 
5.3% vs. 2.1% (p < 0.001) in the case of those 
who declared that a cardiologist or a physician in 
a hospital outpatient clinic had decided about the 
patient’s treatment, 13.6% vs. 6.9% vs. 2.3% vs. 
3.8% (p < 0.001) in the case of participants who 
declared that a  primary care physician decided 
about their treatment, and 23.3% vs. 10.5% vs. 
1.8% vs. 3.0% (p < 0.001) in the case of patients 
treated in private cardiology practices. The time 
trends in the analyzed groups were similar with 
the exception of lipid-lowering agents (p-value 
for the interaction between surveys and groups: 
Table I. Characteristics of the study group by site of care provided after hospitalization
Parameter Practice setting P-value Total
N = 1924
Hospital 
outpatient 
clinic
/cardiologist 
N = 1086
General 
practitioner
N = 634
Private 
cardiology 
practice
N = 204
Age [years] 61.8 ±9.2 60.5 ±8.7 61.5 ±8.9 0.01 61.4 ±9.0
Sex (%): 0.07
Men 67.2 72.2 66.7 68.8
Women 32.8 27.8 33.3 31.2
Duration of education [years] 11.7 ±3.4 11.1 ±3.3 12.7 ±3.9 < 0.001 11.6 ±3.4
Professionally active (%) 20.8 19.7 31.9 < 0.01 21.6
Index event (%): < 0.001
Myocardial infarction 26.4 29.0 33.3 28.0
Unstable angina 26.2 27.0 27.9 26.6
PCI 32.0 19.2 24.5 27.0
CABG 15.5 24.8 14.2 18.4
Hospitalization in (%): < 0.001
Teaching hospital 60.5 46.4 43.1 54.0
Non-teaching hospital 39.5 53.6 56.9 36.0
Smoking (%)* 24.9 34.5 23.5 < 0.001 27.9
Hypertension (%)** 74.7 69.7 70.6 0.07 72.6
Dyslipidemia (%)** 69.7 58.2 61.3 < 0.001 64.0
Diabetes (%)** 24.3 22.4 20.6 0.42 23.3
Obesity (%)** 21.1 15.9 17.7 0.03 19.0
Drugs (%)***:
Antiplatelets 96.4 91.9 94.6 < 0.001 94.7
β-blockers 81.3 74.2 75.0 < 0.01 78.3
ACE inhibitors/sartans 76.0 65.9 70.6 < 0.001 72.1
Lipid-lowering drugs 77.5 55.7 68.1 < 0.001 69.3
*Within 1 month before index hospitalization, **diagnosed during index hospitalization, ***prescribed at discharge. PCI – percutaneous 
coronary intervention, CABG – coronary artery bypass grafting.
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Table II. Proportions of patients with non-controlled risk factors 6–18 months after discharge. The differences were 
adjusted for age, sex, education, professional activity, hospital setting, and index event
Variable Practice setting P-value Total
Hospital 
outpatient 
clinic
/cardiologist 
General 
practitioner
Private 
cardiology 
practice
Smoking:
1997–1998 (%) 16.0 17.5 7.0 0.12 15.7
1999–2000 (%) 12.1 18.5 7.9 0.12 15.3
2006–2007 (%) 16.4 23.8 17.5 0.05 19.1
2011–2013 (%) 16.4 34.0 19.7 0.30 18.3
P-value < 0.01 < 0.01 0.06 < 0.001
All (%) 15.8 21.0 14.2 0.02
Blood pressure ≥ 140/90 mm Hg:
1997–1998 (%) 44.6 47.7 44.2 0.69 45.9
1999–2000 (%) 53.0 47.8 55.3 0.25 50.4
2006–2007 (%) 50.4 45.3 41.1 0.38 47.6
2011–2013 (%) 42.4 52.8 42.2 0.31 43.3
P-value < 0.01 0.53 0.75 0.06
All (%) 46.3 47.5 44.8 0.97
LDL cholesterol not at goal*:
1997–1998 (%) 42.5 51.4 52.4 0.73 47.5
1999–2000 (%) 59.6 70.6 65.8 0.34 66.3
2006–2007 (%) 38.9 41.4 33.3 0.78 39.1
2011–2013 (%) 71.2 79.6 72.4 0.36 72.1
P-value < 0.001 < 0.001 < 0.01 < 0.001
All (%) 56.3 58.0 55.4 0.75
BMI ≥ 30 kg/m2 :
1997–1998 (%) 25.9 27.6 9.3 0.03 24.9
1999–2000 (%) 30.2 25.0 28.9 0.19 27.2
2006–2007 (%) 32.6 34.1 35.7 0.49 33.5
2011–2013 (%) 34.5 28.3 34.8 0.89 34.0
P-value 0.26 0.15 0.02 < 0.01
All (%) 32.0 28.5 28.6 0.37
Fasting glucose ≥ 7.0 mmol/l:
1997–1998 (%) 6.9 12.4 12.2 0.18 9.8
1999–2000 (%) 11.0 16.3 5.3 0.30 13.4
2006–2007 (%) 13.0 13.7 10.7 0.82 13.0
2011–2013 (%) 16.2 16.3 10.3 0.62 15.6
P-value 0.01 0.69 0.79 0.09
All (%) 13.0 14.5 9.4 0.39
BMI – body mass index.
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antiplatelets 0.36, β-blockers 0.25, ACE inhibitors/
sartans 0.25, lipid-lowering drugs < 0.001). The re-
sults did not change significantly when prescribed 
drugs at discharge from the index hospitalization 
were included in the statistical model (data not 
presented).
Table IV presents the values of the secondary 
prevention coefficient by survey and practice set-
ting. When adjusted for confounding variables, 
the coefficient changed over time (Table IV). The 
interaction between surveys and groups was not 
significant (p = 0.49), thus suggesting a similar re-
lationship between the surveys in each analyzed 
group. The results did not change significantly 
when the presence of risk factors during the in-
dex hospitalization and the prescribed drugs at 
Table III. Proportions of patients taking cardioprotective drugs 6–18 months after discharge. The differences were 
adjusted for age, sex, education, professional activity, hospital setting, and index event
Variable Practice setting P-value Total
Hospital 
outpatient 
clinic
/cardiologist 
General 
practitioner
Private 
cardiology 
practice
Antiplatelet:
1997–1998 (%) 83.5 72.9 67.4 0.25 77.2
1999–2000 (%) 91.9 85.8 81.6 0.26 87.6
2006–2007 (%) 89.1 90.0 94.7 0.44 90.1
2011–2013 (%) 90.9 88.7 92.4 0.70 90.8
P-value < 0.01 < 0.01 < 0.01 < 0.001
All (%) 89.3 83.5 85.8 0.03
β-blocker:
1997–1998 (%) 65.4 54.2 62.8 0.51 60.3
1999–2000 (%) 67.8 62.5 65.8 0.98 64.7
2006–2007 (%) 86.1 89.5 84.2 0.41 87.1
2011–2013 (%) 81.7 71.7 84.8 0.11 81.2
P-value < 0.001 < 0.001 0.01 < 0.001
All (%) 78.0 68.3 76.5 < 0.01
ACE inhibitor/sartan:
1997–1998 (%) 42.0 49.7 53.5 0.44 46.6
1999–2000 (%) 50.3 45.3 55.3 0.17 48.0
2006–2007 (%) 79.3 80.1 78.9 0.82 79.6
2011–2013 (%) 78.8 77.4 69.7 0.27 77.7
P-value < 0.001 < 0.001 0.02 < 0.001
All (%) 68.6 58.6 66.2 < 0.01
Lipid-lowering agent:
1997–1998 (%) 48.9 18.6 32.6 < 0.001 34.1
1999–2000 (%) 57.0 34.5 34.2 0.02 42.5
2006–2007 (%) 86.8 87.1 80.7 0.43 86.2
2011–2013 (%) 87.1 69.8 80.3 < 0.01 84.8
P-value < 0.001 < 0.001 < 0.001 < 0.001
All (%) 76.3 47.2 61.8 < 0.001
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Table IV. Secondary prevention coefficient by survey and practice setting. The differences were adjusted for age, 
sex, education, professional activity, hospital setting, and index event
Antiplatelet Practice setting P-value Total
Hospital 
outpatient clinic
/cardiologist 
General 
practitioner
Private 
cardiology 
practice
1997–1998 5.22 ±1.29 5.10 ±1.25 5.41 ±1.05 0.24 5.19 ±1.25
1999–2000 5.18 ±1.25 4.90 ±1.25 5.24 ±1.38 0.48 5.03 ±1.27
2006–2007 5.87 ±1.28 5.61 ±1.26 5.89 ±1.14 0.28 5.78 ±1.26
2011–2013 5.37 ±1.29 4.91 ±1.06 5.37 ±1.25 0.03 5.33 ±1.27
P-value < 0.001 < 0.001 0.05 < 0.001
All 5.45 ±1.31 5.15 ±1.27 5.50 ±1.22 < 0.001
discharge from the index hospitalization where 
included in the statistical model (data not shown).
Discussion
In general, despite the passing of two decades, 
our results showed a  considerable potential for 
a further reduction in cardiovascular risk following 
hospitalization for CAD. The potential for further 
decreasing cardiovascular risk in CAD patients 
has only slightly fallen since 1997/98. Although 
we found a  higher rate of smoking in patients 
who declared that a primary care physician decid-
ed about their treatment, even when multivariate 
adjustments were made, it should be underlined 
that unidentified differences between the ana-
lyzed groups could be responsible for the differ-
ence. We found no major difference in the control 
of other risk factors between the groups defined 
by the site of care. 
Importantly, we found similar changes in the 
implementation of the preventive guidelines ir-
respectively of the practice setting. Indeed, con-
trol of risk factors and the use of cardioprotec-
tive medications changed similarly regardless of 
whether the patients were treated in hospital out-
patient clinics, by primary care physicians or by 
cardiologists in their private practices. 
According to the recent AMI-PL report, the aver-
age number of visits to a primary care clinic made 
by survivors of myocardial infarction was 7.7 per 
year in 2012, whereas the average number of 
consultations with a cardiologist was 1.8 per year 
[16]. Although we found that the majority of the 
last survey participants declared that their treat-
ment had been decided by a  cardiologist, these 
results should not be seen as contradictory. Rath-
er, our results suggest that in the opinion of pa-
tients with CAD most primary care physicians do 
not change therapy prescribed by a  cardiologist. 
Indeed, it seems patients with CAD recognize now 
that the treatment prescribed at discharge from 
the hospital usually is not modified during the fol-
lowing months. This may also explain the relative-
ly small difference in the service quality provided 
by cardiologists and primary care physicians. In 
addition, our results may confirm the decreasing 
esteem of primary care providers among coronary 
patients in Poland. It should also be noted that 
in contrast to the AMI-PL report, we included not 
only patients who had experienced an acute coro-
nary syndrome but also patients who had under-
gone planned revascularization procedures.
We found the secondary prevention coeffi-
cient to be significantly lower in 2011–2013 as 
compared with 2006–2007. This difference does 
not necessarily indicate a  decline in the quality 
of medical care in the field of secondary preven-
tion, as the difference was mainly driven by the 
difference in the proportions of patients with LDL 
cholesterol at recommended goal. Indeed, the 
recommended goal of lipid-lowering therapy in 
2006–2007 was LDL cholesterol below 2.5 mmol/l, 
whereas from 2011 the goal was < 1.8 mmol/l. It is 
possible that the information about the new goal 
did not spread fast enough. Another explanation 
might be the well-known therapeutic inertia [17]. 
In contrast to common beliefs, our results do not 
support the opinions on significantly shorter de-
lays in spreading new guidelines among cardiolo-
gists as compared to primary care physicians. It is 
also possible that knowledge about side-effects of 
therapy could prevent physicians from prescribing 
and patients from taking drugs, especially in high 
doses [18–20]. Another possible explanation for 
the decrease in the secondary prevention coeffi-
cient in 2011–2013 could be a slightly lower par-
ticipation rate compared to previous surveys [4–6, 
8]. It is possible that patients in better condition 
could decide more often not to participate in the 
survey. 
We are unaware of any study published in re-
cent years which was designed to compare sec-
ondary prevention of CAD in different practice 
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settings in Poland. However, recent evidence 
suggests at least comparable potential for im-
provement in other parts of Poland, both in pa-
tients treated by cardiologists and those treated 
by primary care physicians [21–26]. This was also 
shown in patients undergoing bypass surgery 
and other forms of cardiovascular disease [27]. It 
should be stressed that the prescription rates for 
cardiopreventive medications in Poland are similar 
to the average prescription rates in centers par-
ticipating in the EUROASPIRE IV survey and much 
higher compared to centers from high-income 
countries participating in the PURE study [11, 28]. 
Organizational interventions for the secondary 
prevention of CAD have been shown to reduce 
mortality in CAD patients [29]. Many experts sug-
gest the need to implement educational programs 
in clinical practice [24, 30]. Recently, experts of 
the Polish Cardiac Society described a  new or-
ganizational system (named “Optimal Model of 
Comprehensive Rehabilitation and Secondary 
Prevention”), involving both exercise-based reha-
bilitation and education intervention, the wide-
spread implementation of which in Poland could 
be related to a decrease in the number of deaths 
by 3389, in the number of myocardial infarctions 
by 3872, in the number of myocardial revascular-
ization procedures by 13 499, and in the number 
of cardiac hospitalizations by 23 182 yearly [31]. 
The present study has some limitations. Firstly, 
it is possible that some unidentified differences 
between practice setting groups exist. These dif-
ferences may have influenced the approach to sec-
ondary prevention in study participants. Secondly, 
we were not able to assess the impact of the dif-
ferences in secondary prevention implementation 
on the risk of cardiovascular events. Thirdly, our 
study participants were not representative of all 
CAD patients. Participants were limited to those 
who had undergone an acute CAD event or a re-
vascularization procedure. Therefore, our results 
should not be directly applied to other subjects. 
However, an important strength of our analysis is 
that our results are not based just on abstracted 
medical record data but on face-to-face interviews 
and examinations using the same protocol and 
standardized methods and instruments, including 
central laboratory analyses of lipids and glucose. 
Therefore, this analysis provides reliable informa-
tion on lifestyle, risk factors, and therapeutic man-
agement for secondary prevention of CAD over 
the period 1997–2013. 
In conclusion, the control of cardiovascular risk 
in CAD patients has only slightly improved since 
1997–1998 in all health care settings. The great-
est potential for further improvement was found 
among patients whose post-hospital care is pro-
vided by primary care physicians, and it is associ-
ated with promotion of a no-smoking policy and 
enhanced prescription of guideline-recommended 
drugs.
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